Advisors Asset Management Inc. purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 335,174 shares of the company's stock, valued at approximately $48,704,000.
Other institutional investors have also modified their holdings of the company. Beta Wealth Group Inc. boosted its holdings in shares of Merck & Co., Inc. by 17.6% in the third quarter. Beta Wealth Group Inc. now owns 6,849 shares of the company's stock worth $995,000 after buying an additional 1,027 shares during the period. Private Wealth Asset Management LLC boosted its stake in Merck & Co., Inc. by 285.9% in the 3rd quarter. Private Wealth Asset Management LLC now owns 85,114 shares of the company's stock worth $12,489,000 after purchasing an additional 63,059 shares during the period. Alteri Wealth LLC boosted its stake in Merck & Co., Inc. by 4.1% in the 3rd quarter. Alteri Wealth LLC now owns 5,946 shares of the company's stock worth $864,000 after purchasing an additional 234 shares during the period. Private Advisor Group LLC grew its position in Merck & Co., Inc. by 39.6% during the 3rd quarter. Private Advisor Group LLC now owns 372,092 shares of the company's stock worth $54,069,000 after purchasing an additional 105,526 shares in the last quarter. Finally, Tyche Wealth Partners LLC grew its position in Merck & Co., Inc. by 44.0% during the 3rd quarter. Tyche Wealth Partners LLC now owns 12,360 shares of the company's stock worth $1,796,000 after purchasing an additional 3,777 shares in the last quarter. Institutional investors own 76.07% of the company's stock.
Merck & Co., Inc. Stock Down 3.7%
MRK opened at $132.74 on Friday. The business has a 50-day moving average of $145.49 and a 200-day moving average of $129.20. Merck & Co., Inc. has a fifty-two week low of $93.90 and a fifty-two week high of $156.92. The company has a market capitalization of $327.24 billion, a PE ratio of 44.16, a price-to-earnings-growth ratio of 6.32 and a beta of 0.13. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $2.49 EPS for the quarter, topping the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The company had revenue of $18.09 billion for the quarter, compared to analyst estimates of $17.33 billion. During the same quarter in the prior year, the business posted $2.58 EPS. Merck & Co., Inc.'s quarterly revenue was up 4.7% on a year-over-year basis. Equities research analysts forecast that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.
Merck & Co., Inc. Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 8th. Shareholders of record on Tuesday, December 15th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This is a positive change from Merck & Co., Inc.'s previous quarterly dividend of $0.85. This represents a $3.52 annualized dividend and a yield of 2.7%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 350.52%.
Analyst Upgrades and Downgrades
Several analysts have issued reports on the stock. Sanford C. Bernstein boosted their target price on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the company a "market perform" rating in a research note on Tuesday, August 4th. HSBC raised their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. Leerink Partners lifted their price target on Merck & Co., Inc. from $127.00 to $161.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. Wall Street Zen upgraded Merck & Co., Inc. from a "hold" rating to a "strong-buy" rating in a report on Saturday, November 7th. Finally, Argus initiated coverage on Merck & Co., Inc. in a research report on Tuesday, November 3rd. They set a "strong-buy" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $155.74.
View Our Latest Research Report on MRK
Merck & Co., Inc. News Roundup
Here's some of the latest news about MRK:
- Positive Sentiment: A German court overturned a preliminary injunction that had barred Merck from offering its subcutaneous Keytruda formulation in Germany. This removes an immediate obstacle to distribution, though Halozyme says it will pursue a separate patent-infringement lawsuit seeking permanent relief. Article: Halozyme slips as German court overturns injunction against Merck
- Positive Sentiment: Merck increased its quarterly dividend 3.5% to $0.88 per share, supporting its income appeal. Article: Merck dividend announcement
- Negative Sentiment: Merck halted development of nemtabrutinib and ended its Phase 3 BELLWAVE studies after concluding the candidate’s benefit-risk profile did not justify continuing. The move removes a late-stage blood-cancer program from its pipeline. Article: Merck Ends Nemtabrutinib Development
Insider Buying and Selling
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the firm's stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $148.01, for a total transaction of $8,611,961.85. Following the transaction, the executive vice president directly owned 112,955 shares in the company, valued at $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.17% of the stock is owned by insiders.
Merck & Co., Inc. Profile
(
Free Report)
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.